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Parameters Before RT After RT
10-TSS (seconds) 27.976.4 21.974.1*
SS-60 (repetitions) 26.076.7 28.975.7*
Muscle mass - men (kg) 48.079.1 51.5710*
Muscle mass - women (kg) 34.174.4 36.974.9*
Body fat - men (%) 29.275.1 25.375.1*
Body fat - women (%) 34.675.1 32.474.7*
LG- Proximal -R (cm) 53.676.6 55.476.7*
LG- Proximal -L (cm) 52.775.8 54.176.7
LG- Medial -R (cm) 46.875.1 48.674.9*
LG- Medial -L (cm) 46.674.4 48.575.4*
LG- Leg circumference; R-right; L- left;
n
po0.01.
http://dx.doi.org/10.1016/j.krcp.2012.04.491
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IMPROVING EFFICIENCY OF DIETETIC SERVICES IN CHRONIC KIDNEY
DISEASE WITH A CATEGORISED REFERRAL TOOL
Belinda Morey
Royal Brisbane and Women’s Hospital, Australia
Over the past 3 years the number of CKD patients attending our renal
outpatient service has increased dramatically from under 100 to over 400
patients. In this time dietetic resources within this service have remained
unchanged. This has presented challenges for meeting current practice
guidelines and has created long waiting lists to see the dietitian.
The aim of this project was to determine the current status of dietetic
appointments and reasons for referral. Using this information we proposed
to develop a new referral tool and booking procedures to enable clear
prioritization of patients and appropriate referral pathways.
A nurses’ perceptions questionnaire and a 4-week audit of appointments
were conducted. The new referral tool and booking procedures included
categorisation of clinical dietetic priority, utilisation of other community
dietetic services where appropriate, and explanatory notes of which
patients should take priority in fully booked clinics.
At baseline, it was found that 18 of 57 (31.6%) attempts to book dietetic
appointments were not successful due to fully booked clinics (7 new and
11 reviews). While 6 of the 11 reviews were for reasons of higher dietetic
urgency e.g. hyperkalaemia and malnutrition, 6 out of 7 new referrals were
for lifestyle related reasons e.g. obesity, diabetes, and cholesterol. It is felt
the new categorised referral tool and pathways will provide better
guidance for referral and appropriate use of dietetic resources for CKD
management, to be evaluated in early 2012.
http://dx.doi.org/10.1016/j.krcp.2012.04.492
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THE ROLE OF SALIVARY GLANDS IN PHOSPHATE HOMEOSTASIS
Tomo Mukai 1, Hiroko Segawa 1, Shohei Sasaki 1, Saori Ohnishi 1,
Yasuko Ishikawa 2, Naoshi Horiba 3, Otoya Ueda 3, Kou-ichi Jishage 3,
Naoshi Fukushima 3, Sawako Tatsumi 1, Shinsuke Kido 1,
Ken-ichi Miyamoto 1
1
Department of Molecular Nutrition
2
Department of Molecular Nutrition and Department of Medical
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Hyperphosphatemia is recognized as a contributor to vascular
calciﬁcation in patients with chronic kidney disease (CKD) and
hemodialysis (HD) patients and is independently associated with cardiac
mortality. Dietary inorganic phosphorus (Pi) restriction, and the Pi binders
are important therapy for dialysis patients with hyperphosphatemia.
Recent study reported that salivary secretion of Pi to be an important
determinant of hyperphosphatemia in patients with CKD and in those with
ESRD under chronic dialysis. In the present study, we investigated the role
of type IIb sodium-dependent Pi transporter (Npt2b) on salivary Pi
excretion in mice.
The expression of Npt2b protein was detected at the apical side of duct
cells in the salivary glands, suggesting that ductal cells appears to be able
to reabsorb Pi, thereby modifying the Pi concentration in the ﬁnal saliva. In
wild-type mice (Wt mice) fed a high Pi diet, the levels of plasma and
salivary Pi are signiﬁcantly higher than those in mice fed a low Pi diet.
In Npt2bþ /- mice, the salivary Pi concentrations were signiﬁcantly increased
compared with those in Npt2bþ /þ mice. Npt2bþ /- mice with adenine-induced
renal failure had low plasma and salivary Pi levels, and plasma creatinine and
BUN levels compared with Npt2bþ /þ mice treated with adenine. In conclusion,
Npt2b is involved in Pi secretion by salivary glands.
http://dx.doi.org/10.1016/j.krcp.2012.04.493
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A MODIFIED MEAL REPLACEMENT PLAN AS WEIGHT LOSS TREATMENT
IN CHRONIC KIDNEY DISEASE: A CASE STUDY
Belinda Morey, Jillian Murray
Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
Low calorie liquid meal replacements can be used to achieve weight loss
in obese patients. Many consider renal disease a contraindication to this
due to a lack of speciﬁc research. The aim of this case study is to illustrate
that this therapy can be used effectively in Chronic Kidney Disease (CKD).
After numerous failed weight loss attempts, the multidisciplinary team
(Nephrology, Endocrinology, General Practice and Dietetics) decided to trial a
65 year old patient (CKD Stage 3 secondary to Type 2 Diabetes Mellitus
requiring insulin) on a modiﬁed meal replacement plan. This plan consisted of
3 Optifast meal replacement drinks plus one portion controlled meal, (4MJ
and 85g of protein per day). Monitoring included frequent blood glucose self
testing, fortnightly blood tests and review by the Dietitian (monthly once
stable). The patient was initially unable to exercise due to pain.
At baseline, weight was 157 kg (BMI: 41 kg/m2), waist circumference 155cm
and blood biochemistry indicated CKD stage 3b (eGFR: 39 ml/min, Urea:
15.9 mmol/L, Creat: 156 umol/L). After 14 weeks weight had decreased 22 kg
(BMI: 35.8 kg/m2), waist circumference had decreased 18 cm and reported pain
improved. Insulin requirements approximately halved, and blood biochemistry
(eGFR: 42ml/min, Urea: 15.2 mmol/L, Creat: 147 umol/L) indicated no decline
in renal function. With close monitoring a modiﬁedmeal replacement plan was
used successfully in a patient with CKD however prospective randomised trials
are required to further investigate this treatment.
http://dx.doi.org/10.1016/j.krcp.2012.04.494
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INFLUENCE OF INTENSIVE EXERCISE ON RENAL FUNCTIONS (RF) AND
ADVANCED GLYCATION END-PRODUCTS (AGES)
Miroslav Mydlk 1,2, Katarna Derzsiova 1, Katarna Sebekova 3,
Michal Farkas 4, Beata Hvozdovicova 4, Anna Chmelarova 2
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Under certain pathologic conditions AGEs formation can be increased
beyond normal levels.The purpose of the study was to investigate essential
RF and AGEs before, immediately after and 2 days after runs. Nine trained
runners (4379yr) during 9.5 km and 13 trained runners (48711yr)
during 16.3 km long-distance runs were investigated. Standard blood and
urinary RF parameters were investi-gated in all runners using
spectrophotometric methods by Roche analyzer Integra 800.Serum cystatin
C was determined using immu-noturbidimetric method (PETIA Gentian).
Plasma AGEs and malon-dialdehyde (MDA) were determined by
spectroﬂuorimetric methods, Ne-carboxylmethyllysine using ELISA method
and advanced oxidation protein products(AOPPs) using
spectrophotometric method.
Total proteinuria was 0.4670.4 g/L after 9.5 km run and 0.3570.3 g/L
after 16.3 km run. Serum urea and creatinine signiﬁcantly increased after
both runs (creatinine in 28% after 9.5 km and in 41% after 16.3 km run).
Estimated glomerular ﬁltration rate (eGFR) MDRD and eGFR-PETIA
signiﬁcantly decreased after both runs (9.5 km: in 27.6% resp. 21.3% and
16.3 km: in 34,6% resp. 30.3%, po0.01). Direct relationship between serum
cystatin C and plasma AGEs after 16.3 km run was found (r¼0.66, p¼
0,014). No signiﬁcant changes in plasma AGEs (from 277786—2867
72 resp. from 283764—292790 AU), CML (from 619778–6657131
resp. from 724792—7627135 ng/mL) and AOPPs (from 151758—1067
21 resp. from 1597100–133767 mmol/L) were found after both runs.
Plasma MDA decreased after both runs.
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In conclusion, RF abnormalities in runners were caused by dehydration,
protein catabolism, rhabdomyolysis and others. These RF changes were not
present or parameters not signiﬁcantly differed from initial values 2 days
after both runs. Plasma AGEs and AOPPs in runners were in reference
ranges, no signiﬁcant changes during the both runs were observed.
http://dx.doi.org/10.1016/j.krcp.2012.04.495
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A POPULATION PHARMACOKINETIC (PK)- PHARMACODYNAMIC (PD)
ANALYSIS OF PEGINESATIDE INDIA LYSIS PATIENTS WITH CHRONIC
KIDNEY DISEASE
Himanshu Naik, Max Tsai, Ping Qiu, Majid Vakilynejad
Takeda Global Research & Development Ctr, Inc., Deerﬁeld, IL, USA
Peginesatide is an erythropoiesis stimulating agent (ESA) being developed for
the treatment of anemia due to chronic kidney disease in dialysis patients. The
purpose of this analysis was to develop a population PK-PD model to
characterize time-course of peginesatide plasma and hemoglobin (Hb)
concentrations following administration of IV and SC peginesatide injections.
This population PK–PD analysis included 4 phase 2 studies and 1 phase 3 study.
Baseline subject demographics, laboratory values, and concomitant
medications were evaluated as covariates in a stepwise manner. Models were
evaluated for goodness-of-ﬁt using diagnostic plots, predictability based on
visual predictive check, and stability based on bootstrap analyses. The ﬁnal PK
model was a two compartment model with ﬁrst-order absorption and
saturable elimination. The ﬁnal PD model was a precursor-dependent indirect
response model with parameters accounting for the residual effect from the
previous ESA doses (ESAD) and apparent change in disease condition (CF). The
PD parameters shown below were estimated with good precision(relative
standard error[RSE] r2%).
Parameters Estimate RSE%
EC50 (ng/mL) 401 2.0
Emax 0.542 1.6
Baseline Hb (g/dL) 11.5 0.40
MTT (mean transit time for red blood cells, h) 1640 0.49
MTP (mean transit time for progenitor cells, h) 462 1.1
ESA (residual effect from the previous ESA 0.153 0.66
CF (correction factor for disease condition) 0.000275 0.87
Total bilirubin, body mass index, age, alkaline phosphatase, ethnicity, and
serum creatinine (for non-dialysis subjects) for PK and age and ESAD for PD
were identiﬁed as statistically signiﬁcant (p-valueo0.005) covariates.
None of these identiﬁed covariates were considered to be clinically
relevant, based on their impact on simulated peginesatide exposure
(o730%) and Hb (o0.2 g/dL) levels.
http://dx.doi.org/10.1016/j.krcp.2012.04.496
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PUTATIVE ROLE OF FGF 23 IN THE DEVELOPMENT OF
HYPOPHOSPHATEMIA AND BONE FRUCTURES IN AN ANEMIC PATIENT
TREATED BY INTRAVENOUS SACCHARATED FERRIC OXIDE
Risa Ishida, Shohei Nakanishi, Sachie Hisose, Jong Il Kim
Masafumi Fukagawa Chibune Hospital, Osaka city, JAPAN
A post-menopausal patient with normal kidney function was referred to
our hospital because of severe lumber pain. She had been treated by
initially oral, and then by intravenous iron for longer than ﬁve years for the
treatment of iron deﬁciency anemia due to recurrent GI bleeding. On
admission, multiple lumber bone fracture with low bone mineral density
was conﬁrmed. Laboratory tests revealed severe hypophosphatemia (1.6
mg/dl) with slight decrease of calcium ion level. Serum levels of 25D and
1,25D were low normal, while increase of intact PTH (83.9 pg/ml) and
FGF23 (60 pg/ml) were observed. After terminating intravenous iron
supplement, her symptoms and hypophsophatemia were gradually
normalized with oral active vitamin D treatment. Although we could not
completely exclude the contribution of disturbed iron absorption from the
intestine, damages of proximal tubular cells by iron, and osteomalacia
caused by the deposition of iron, increased FGF23 level may have played
critical roles in the development of severe hypophosphatemia in this
patient. Such hypophosphatemia due to high FGF23 has recently been
reported in patients treated by intravenous sacharated ferric oxide.
http://dx.doi.org/10.1016/j.krcp.2012.04.497
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THE EATING AT TREATMENT (EAT) QUESTIONNAIRE: A TOOL TO ASSESS
HABITS RELATED TO PATIENTS EATING AT DIALYSIS
Mary Burgess 1, Maria Stasios 2, Marcia Davis 2, Deborah Benner 2
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Within the US, the policies at dialysis facilities differ as to whether patients
(pts) are permitted to eat or not while being treated. The Eating At Treatment
(EAT) pilot program was designed to determine whether educating pts and
allowing them to eat on dialysis would reduce the number of missed meals on
dialysis days and potentially improve nutritional status. The EAT questionnaire
was developed as a tool to assess eating habits of pts on days they received
dialysis treatment vs non-treatment days. Seven Registered Dietitians (RDs)
administered the EAT questionnaire to 61 pts.
Patients reported eating a different number of meals/day (2.32 vs 2.69) and
snacks/day (1.09 vs 1.36) on treatment vs non-treatment days, respectively. Of
the pts who ate at the dialysis facility, 86% reported that they ate during
treatment as opposed to before or after treatment. Of the pts who did not eat at
the dialysis facility, the most common reported reasons were that they were
not hungry (63%) or reported an adverse event (eg., stomach pain, risk of
diarrhea, hypotension) (20%). Reported dietary intake from 37 pts who ate
during dialysis was scored by RDs for protein and kcal content. Adequate intake
was set at 4 200 kcal for calorie intake and 4 10 g of protein for protein
intake. Nineteen (51%) pts reported adequate kcal intake, while only 12 (32%)
pts reported adequate protein intake.
Based on results obtained from this small pilot questionnaire, pts reported
eating less on treatment days vs non-treatment days. In addition, pts reported
that their intake at treatment was low in protein. This questionnaire has proven
to be an effective tool that is easy to administer and score (total time 12min/
pt) for providing insight into the eating habits of pts receiving dialysis
treatment. An opportunity exists for educating pts through nutritional
counseling about increasing their protein and kcal intake on treatment days.
Distribution of this questionnaire to a large number of dialysis pts may prove
useful for reevaluating policies regarding eating at dialysis centers.
http://dx.doi.org/10.1016/j.krcp.2012.04.498
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PRACTICES AND OPINIONS ON IN-CENTER FOOD CONSUMPTION ACROSS
1,223 FACILITIES IN THE UNITED STATES
Deborah Benner 1, Marcia Davis 1, Maria Stasios 1, Mary Burgess 2
1
DaVita Inc, Denver, CO
2
DaVita Clinical Research, Minneapolis, MN
In the United States, the practices and opinions of healthcare providers
regarding eating on dialysis are unknown. The purpose of this study was to
understand healthcare provider opinions and in-center hemodialysis
patient practices regarding eating while at the dialysis center. In June 2011,
over 1200 registered dietitians within a large dialysis organization in the
US were surveyed on current practices and opinions of patient food
consumption during dialysis treatment using an online survey.
1223 of 1665 (73%) dialysis facilities responded to the food consumption
survey.
n¼1222 Permitted No Guidelines Not allowed
n (%) n (%) n (%)
Eating on dialysis 803 (66%) 67 (5%) 352 (29%)
Drinking on dialysis 907 (75%) 87 (7%) 228 (19%)
218 (18%) of the respondents stated that the facility practice for
consuming nutritional supplements (eg., liquid nutritional supplements
and/or protein bars) while on dialysis was different than the policy for
consuming food while on dialysis. Interestingly, 1203 (98%) of the
respondents stated consuming food before or after dialysis was allowed.
The top reasons for facility practices that allowed eating during dialysis
were: prevention of hypoglycemia on dialysis, improved kcal intake on
dialysis days, and the opportunity to provide counseling on food products
currently chosen by the patient. The top reasons for facility practices not
permitting eating during dialysis included: potential adverse events
associated with hypotension, GI symptoms, choking, infection, pest control,
and spills. Further analyses are warranted to determine whether there is a
correlation between allowing patients to eat during dialysis treatment and
an improvement in the nutritional status of the patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.499
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